Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection

Nagao Shinagawa, Akihiko Iwai, Yoshitaka Shibata, Keiichi Hori, Yasuo Sawada, Hisashi Okubo, Tsuyoshi Takahashi, Ikuo Hashimoto, Takashi Nakamura, Takashi Hirayama, Kyuya Ishibiki, Toshiharu Furukawa, Takashi Tanaka, Masahiko Kunimatsu, Shigetomi Iwai, Komei Kato, Yoshinobu Sumiyama, Shinya Kusachi, Yoichi Arima, Takeshi AoyagiAkio Nakayoshi, Kazuo Kimura, Osamu Sakurai, Katsuhiko Nohga, Takeaki Shimizu, Osamu Sato, Kazue Ozawa, Taisuke Morimoto, Hiroaki Kinoshita, Ken Morimoto, Shuichi Nakatani, Shoji Kubo, Mikio Fujimoto

Research output: Contribution to journalArticle

Abstract

The clinical effects of a newly developed quinolone antimicrobial drug for oral use, grepailoxacin (GPFX), on infectious diseases in the surgical field were investigated by 13 collaborating organizations and 4 related institutions throughout the country. The results were as follows. GPFX was administered to 183 patients at a dose of 150∼400 mg once or twice a day for 3∼14 days. Eight patients were excluded or dropped out, leaving 177 patients to be evaluated for clinical effects. The efficacy rate was 85.9% in the patients with superficial purulent diseases, 66.7% in those with mastitis, 93.8% in those with periproctal abscess, 81.8% in those with secondary infections (19/23 for postoperative wound, 3/3 for wound, 1/1 for burn, and 4/6 for others), and 94.7% in those with cholecystitis and cholangitis. The total efficacy rate was 85.3%. The efficacy rate in 116 patients in whom bacteria were isolated before the start of administration was 85.3%. Eradication of bacteria could be assessed in 99 patients. The isolates were eradicated or superinfection was observed in 83 patients. The eradication rate was 83.8%. The eradication rate in the 170 strains whose eradication was confirmed was 91.7%(11/12 strains) for Staphylococcus aureus, 92.9%(13/14) for coagulase-negative staphylococci, 100%(13/13) for Staphylococcus epidermidis, 73.3%(11/15) for Escherichia coli and 100%(11/11) for Peptostreptococcus spp. The total rate was 86.5%(147/170). With regard to safety, slight and transient adverse reactions, mainly of bitter taste in the oral cavity, were observed in 7 of the 179 subjects. Abnormal change in s-GPT was observed in one patient on clinical laboratory tests. The above results suggest that GPFX is highly useful for infectious diseases in the surgical field.

Original languageEnglish
Pages (from-to)454-467
Number of pages14
JournalJapanese Journal of Chemotherapy
Volume43
DOIs
Publication statusPublished - 1995

Fingerprint

Quinolones
Infection
Pharmaceutical Preparations
Communicable Diseases
Peptostreptococcus
Bacteria
Superinfection
Cholecystitis
Cholangitis
Staphylococcus epidermidis
grepafloxacin
Mastitis
Coagulase
Wounds and Injuries
Coinfection
Staphylococcus
Abscess
Mouth
Staphylococcus aureus
Escherichia coli

Keywords

  • grepafloxacin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection. / Shinagawa, Nagao; Iwai, Akihiko; Shibata, Yoshitaka; Hori, Keiichi; Sawada, Yasuo; Okubo, Hisashi; Takahashi, Tsuyoshi; Hashimoto, Ikuo; Nakamura, Takashi; Hirayama, Takashi; Ishibiki, Kyuya; Furukawa, Toshiharu; Tanaka, Takashi; Kunimatsu, Masahiko; Iwai, Shigetomi; Kato, Komei; Sumiyama, Yoshinobu; Kusachi, Shinya; Arima, Yoichi; Aoyagi, Takeshi; Nakayoshi, Akio; Kimura, Kazuo; Sakurai, Osamu; Nohga, Katsuhiko; Shimizu, Takeaki; Sato, Osamu; Ozawa, Kazue; Morimoto, Taisuke; Kinoshita, Hiroaki; Morimoto, Ken; Nakatani, Shuichi; Kubo, Shoji; Fujimoto, Mikio.

In: Japanese Journal of Chemotherapy, Vol. 43, 1995, p. 454-467.

Research output: Contribution to journalArticle

Shinagawa, N, Iwai, A, Shibata, Y, Hori, K, Sawada, Y, Okubo, H, Takahashi, T, Hashimoto, I, Nakamura, T, Hirayama, T, Ishibiki, K, Furukawa, T, Tanaka, T, Kunimatsu, M, Iwai, S, Kato, K, Sumiyama, Y, Kusachi, S, Arima, Y, Aoyagi, T, Nakayoshi, A, Kimura, K, Sakurai, O, Nohga, K, Shimizu, T, Sato, O, Ozawa, K, Morimoto, T, Kinoshita, H, Morimoto, K, Nakatani, S, Kubo, S & Fujimoto, M 1995, 'Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection', Japanese Journal of Chemotherapy, vol. 43, pp. 454-467. https://doi.org/10.11250/chemotherapy1995.43.Supplement1_454
Shinagawa, Nagao ; Iwai, Akihiko ; Shibata, Yoshitaka ; Hori, Keiichi ; Sawada, Yasuo ; Okubo, Hisashi ; Takahashi, Tsuyoshi ; Hashimoto, Ikuo ; Nakamura, Takashi ; Hirayama, Takashi ; Ishibiki, Kyuya ; Furukawa, Toshiharu ; Tanaka, Takashi ; Kunimatsu, Masahiko ; Iwai, Shigetomi ; Kato, Komei ; Sumiyama, Yoshinobu ; Kusachi, Shinya ; Arima, Yoichi ; Aoyagi, Takeshi ; Nakayoshi, Akio ; Kimura, Kazuo ; Sakurai, Osamu ; Nohga, Katsuhiko ; Shimizu, Takeaki ; Sato, Osamu ; Ozawa, Kazue ; Morimoto, Taisuke ; Kinoshita, Hiroaki ; Morimoto, Ken ; Nakatani, Shuichi ; Kubo, Shoji ; Fujimoto, Mikio. / Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43. pp. 454-467.
@article{b8de3154271a42938f127d50a7c18407,
title = "Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection",
abstract = "The clinical effects of a newly developed quinolone antimicrobial drug for oral use, grepailoxacin (GPFX), on infectious diseases in the surgical field were investigated by 13 collaborating organizations and 4 related institutions throughout the country. The results were as follows. GPFX was administered to 183 patients at a dose of 150∼400 mg once or twice a day for 3∼14 days. Eight patients were excluded or dropped out, leaving 177 patients to be evaluated for clinical effects. The efficacy rate was 85.9{\%} in the patients with superficial purulent diseases, 66.7{\%} in those with mastitis, 93.8{\%} in those with periproctal abscess, 81.8{\%} in those with secondary infections (19/23 for postoperative wound, 3/3 for wound, 1/1 for burn, and 4/6 for others), and 94.7{\%} in those with cholecystitis and cholangitis. The total efficacy rate was 85.3{\%}. The efficacy rate in 116 patients in whom bacteria were isolated before the start of administration was 85.3{\%}. Eradication of bacteria could be assessed in 99 patients. The isolates were eradicated or superinfection was observed in 83 patients. The eradication rate was 83.8{\%}. The eradication rate in the 170 strains whose eradication was confirmed was 91.7{\%}(11/12 strains) for Staphylococcus aureus, 92.9{\%}(13/14) for coagulase-negative staphylococci, 100{\%}(13/13) for Staphylococcus epidermidis, 73.3{\%}(11/15) for Escherichia coli and 100{\%}(11/11) for Peptostreptococcus spp. The total rate was 86.5{\%}(147/170). With regard to safety, slight and transient adverse reactions, mainly of bitter taste in the oral cavity, were observed in 7 of the 179 subjects. Abnormal change in s-GPT was observed in one patient on clinical laboratory tests. The above results suggest that GPFX is highly useful for infectious diseases in the surgical field.",
keywords = "grepafloxacin",
author = "Nagao Shinagawa and Akihiko Iwai and Yoshitaka Shibata and Keiichi Hori and Yasuo Sawada and Hisashi Okubo and Tsuyoshi Takahashi and Ikuo Hashimoto and Takashi Nakamura and Takashi Hirayama and Kyuya Ishibiki and Toshiharu Furukawa and Takashi Tanaka and Masahiko Kunimatsu and Shigetomi Iwai and Komei Kato and Yoshinobu Sumiyama and Shinya Kusachi and Yoichi Arima and Takeshi Aoyagi and Akio Nakayoshi and Kazuo Kimura and Osamu Sakurai and Katsuhiko Nohga and Takeaki Shimizu and Osamu Sato and Kazue Ozawa and Taisuke Morimoto and Hiroaki Kinoshita and Ken Morimoto and Shuichi Nakatani and Shoji Kubo and Mikio Fujimoto",
year = "1995",
doi = "10.11250/chemotherapy1995.43.Supplement1_454",
language = "English",
volume = "43",
pages = "454--467",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",

}

TY - JOUR

T1 - Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection

AU - Shinagawa, Nagao

AU - Iwai, Akihiko

AU - Shibata, Yoshitaka

AU - Hori, Keiichi

AU - Sawada, Yasuo

AU - Okubo, Hisashi

AU - Takahashi, Tsuyoshi

AU - Hashimoto, Ikuo

AU - Nakamura, Takashi

AU - Hirayama, Takashi

AU - Ishibiki, Kyuya

AU - Furukawa, Toshiharu

AU - Tanaka, Takashi

AU - Kunimatsu, Masahiko

AU - Iwai, Shigetomi

AU - Kato, Komei

AU - Sumiyama, Yoshinobu

AU - Kusachi, Shinya

AU - Arima, Yoichi

AU - Aoyagi, Takeshi

AU - Nakayoshi, Akio

AU - Kimura, Kazuo

AU - Sakurai, Osamu

AU - Nohga, Katsuhiko

AU - Shimizu, Takeaki

AU - Sato, Osamu

AU - Ozawa, Kazue

AU - Morimoto, Taisuke

AU - Kinoshita, Hiroaki

AU - Morimoto, Ken

AU - Nakatani, Shuichi

AU - Kubo, Shoji

AU - Fujimoto, Mikio

PY - 1995

Y1 - 1995

N2 - The clinical effects of a newly developed quinolone antimicrobial drug for oral use, grepailoxacin (GPFX), on infectious diseases in the surgical field were investigated by 13 collaborating organizations and 4 related institutions throughout the country. The results were as follows. GPFX was administered to 183 patients at a dose of 150∼400 mg once or twice a day for 3∼14 days. Eight patients were excluded or dropped out, leaving 177 patients to be evaluated for clinical effects. The efficacy rate was 85.9% in the patients with superficial purulent diseases, 66.7% in those with mastitis, 93.8% in those with periproctal abscess, 81.8% in those with secondary infections (19/23 for postoperative wound, 3/3 for wound, 1/1 for burn, and 4/6 for others), and 94.7% in those with cholecystitis and cholangitis. The total efficacy rate was 85.3%. The efficacy rate in 116 patients in whom bacteria were isolated before the start of administration was 85.3%. Eradication of bacteria could be assessed in 99 patients. The isolates were eradicated or superinfection was observed in 83 patients. The eradication rate was 83.8%. The eradication rate in the 170 strains whose eradication was confirmed was 91.7%(11/12 strains) for Staphylococcus aureus, 92.9%(13/14) for coagulase-negative staphylococci, 100%(13/13) for Staphylococcus epidermidis, 73.3%(11/15) for Escherichia coli and 100%(11/11) for Peptostreptococcus spp. The total rate was 86.5%(147/170). With regard to safety, slight and transient adverse reactions, mainly of bitter taste in the oral cavity, were observed in 7 of the 179 subjects. Abnormal change in s-GPT was observed in one patient on clinical laboratory tests. The above results suggest that GPFX is highly useful for infectious diseases in the surgical field.

AB - The clinical effects of a newly developed quinolone antimicrobial drug for oral use, grepailoxacin (GPFX), on infectious diseases in the surgical field were investigated by 13 collaborating organizations and 4 related institutions throughout the country. The results were as follows. GPFX was administered to 183 patients at a dose of 150∼400 mg once or twice a day for 3∼14 days. Eight patients were excluded or dropped out, leaving 177 patients to be evaluated for clinical effects. The efficacy rate was 85.9% in the patients with superficial purulent diseases, 66.7% in those with mastitis, 93.8% in those with periproctal abscess, 81.8% in those with secondary infections (19/23 for postoperative wound, 3/3 for wound, 1/1 for burn, and 4/6 for others), and 94.7% in those with cholecystitis and cholangitis. The total efficacy rate was 85.3%. The efficacy rate in 116 patients in whom bacteria were isolated before the start of administration was 85.3%. Eradication of bacteria could be assessed in 99 patients. The isolates were eradicated or superinfection was observed in 83 patients. The eradication rate was 83.8%. The eradication rate in the 170 strains whose eradication was confirmed was 91.7%(11/12 strains) for Staphylococcus aureus, 92.9%(13/14) for coagulase-negative staphylococci, 100%(13/13) for Staphylococcus epidermidis, 73.3%(11/15) for Escherichia coli and 100%(11/11) for Peptostreptococcus spp. The total rate was 86.5%(147/170). With regard to safety, slight and transient adverse reactions, mainly of bitter taste in the oral cavity, were observed in 7 of the 179 subjects. Abnormal change in s-GPT was observed in one patient on clinical laboratory tests. The above results suggest that GPFX is highly useful for infectious diseases in the surgical field.

KW - grepafloxacin

UR - http://www.scopus.com/inward/record.url?scp=0029165382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029165382&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1995.43.Supplement1_454

DO - 10.11250/chemotherapy1995.43.Supplement1_454

M3 - Article

AN - SCOPUS:0029165382

VL - 43

SP - 454

EP - 467

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

ER -